The herpes simplex virus treatment market size valued for $1,724.27 million in 2021 and is estimated to reach $2,126.91 million by 2031, exhibiting a CAGR of 2.1% from 2022 to 2031.
Herpes simplex virus (HSV) is a common viral infection that affects many people worldwide. There are two types of herpes simplex virus including type 1 (HSV-1) and type 2 (HSV-2). HSV-1 is usually associated with oral herpes, causing cold sores or fever blisters around the mouth. This type of herpes also causes genital herpes if it is transmitted through oral sex. HSV-2 is the most common cause of genital herpes, but it also causes oral herpes if it is transmitted through genital-to-oral contact. HSV can spread through sexual contact and virus also be transmitted in other ways. Herpes simplex virus treatment includes antiviral medications, topical creams or ointments, and home remedies to manage symptoms. The use of antiviral drugs has shown promising results in treating the disease.
The global herpes simplex virus treatment market is majorly driven by increase in the incidences of herpes viral infections. In addition, rise in R&D activities for herpes simplex virus and development of newer & advanced formulations, such as tablets and creams, are expected to fuel the market growth. For instance, AiCuris Anti-infective Cures AG is a German biopharmaceutical company that is developing a new antiviral drug (Pritelivir) for the treatment of HSV infections. This drug, Pritelivir, works by inhibiting the virus from replicating and has been shown to be effective in reducing viral shedding and the frequency of infections in clinical trials. Thus, rise in R&D activities for herpes simplex virus propels the market growth.
In contrast, limited awareness about the diseases such as sexually transmitted infections (STIs) and herpes virus in underdeveloped countries impedes the growth of the market. However, there is an increase in awareness of herpes infections, with rise in number of people are getting tested and diagnosed. This leads to increase in the demand for effective treatments in developed countries.
Moreover, development and approvals of drugs for herpes simplex virus and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are anticipated to drive the market growth during the forecast period. For instance, in November 2020, Amneal Pharmaceuticals, LLC announced that it has received the approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%, a generic version of Zovirax for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.
The herpes simplex virus treatment market is segmented into type, drug type, distribution channel, and region. By type, the market is categorized into herpes simplex virus-1 infection, and herpes simplex virus-2 infection. By drug type, the market is classified into acyclovir, valacyclovir, and famciclovir. By distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global herpes simplex virus treatment market are Abbott Laboratories, Amneal Pharmaceuticals LLC., Emcure Pharmaceuticals Limited, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Herpes simplex virus (HSV) is a common viral infection that affects many people worldwide. There are two types of herpes simplex virus including type 1 (HSV-1) and type 2 (HSV-2). HSV-1 is usually associated with oral herpes, causing cold sores or fever blisters around the mouth. This type of herpes also causes genital herpes if it is transmitted through oral sex. HSV-2 is the most common cause of genital herpes, but it also causes oral herpes if it is transmitted through genital-to-oral contact. HSV can spread through sexual contact and virus also be transmitted in other ways. Herpes simplex virus treatment includes antiviral medications, topical creams or ointments, and home remedies to manage symptoms. The use of antiviral drugs has shown promising results in treating the disease.
The global herpes simplex virus treatment market is majorly driven by increase in the incidences of herpes viral infections. In addition, rise in R&D activities for herpes simplex virus and development of newer & advanced formulations, such as tablets and creams, are expected to fuel the market growth. For instance, AiCuris Anti-infective Cures AG is a German biopharmaceutical company that is developing a new antiviral drug (Pritelivir) for the treatment of HSV infections. This drug, Pritelivir, works by inhibiting the virus from replicating and has been shown to be effective in reducing viral shedding and the frequency of infections in clinical trials. Thus, rise in R&D activities for herpes simplex virus propels the market growth.
In contrast, limited awareness about the diseases such as sexually transmitted infections (STIs) and herpes virus in underdeveloped countries impedes the growth of the market. However, there is an increase in awareness of herpes infections, with rise in number of people are getting tested and diagnosed. This leads to increase in the demand for effective treatments in developed countries.
Moreover, development and approvals of drugs for herpes simplex virus and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are anticipated to drive the market growth during the forecast period. For instance, in November 2020, Amneal Pharmaceuticals, LLC announced that it has received the approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%, a generic version of Zovirax for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.
The herpes simplex virus treatment market is segmented into type, drug type, distribution channel, and region. By type, the market is categorized into herpes simplex virus-1 infection, and herpes simplex virus-2 infection. By drug type, the market is classified into acyclovir, valacyclovir, and famciclovir. By distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global herpes simplex virus treatment market are Abbott Laboratories, Amneal Pharmaceuticals LLC., Emcure Pharmaceuticals Limited, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the herpes simplex virus treatment market analysis from 2021 to 2031 to identify the prevailing herpes simplex virus treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the herpes simplex virus treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global herpes simplex virus treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Herpes simplex virus-1 infection
- Herpes simplex virus-2 infection
By Drug type
- Acyclovir
- Valacyclovir
- Famciclovir
By Distribution channel
- Hospital pharmacies
- Drug store and retail pharmacies
- Online providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Viatris Inc.
- Abbott Laboratories
- GlaxoSmithKline plc
- Pfizer Inc.
- Fresenius SE and Co. KGaA
- Amneal Pharmaceuticals LLC
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Emcure Pharmaceuticals Limited
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: HERPES SIMPLEX VIRUS TREATMENT MARKET, BY TYPE
CHAPTER 5: HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DRUG TYPE
CHAPTER 6: HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: HERPES SIMPLEX VIRUS TREATMENT MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report titled, “Herpes Simplex Virus Treatment Market," the herpes simplex virus treatment market size was valued for $1,724.27 million in 2021 and is estimated to reach $2,126.91 million by 2031, exhibiting a CAGR of 2.1% from 2022 to 2031.Herpes simplex virus (HSV) is a highly contagious virus that causes infections in humans. Herpes simplex virus is of two types HSV-1, which typically causes oral herpes, and HSV-2, which typically causes genital herpes. Both types of HSVs are transmitted through direct contact with infected individuals, usually via oral or genital secretions. HSV infection is a highly contagious and can be transmitted through contact with infected skin, mucous membranes, or bodily fluids. Antiviral medications help to manage the symptoms and reduce the frequency of infection.
Key factors driving the growth of the Herpes simplex virus treatment market include increase in people affected with the herpes simplex virus, increase in awareness and education about the risks and consequences of HSV infections. Public health campaigns and educational initiatives have led to improvements in the diagnosis and treatment of HSV infections which supports the market growth. Moreover, governments and non-governmental organizations are taking initiatives to raise awareness about sexually transmitted infections (STIs), including herpes simplex virus. This increased awareness among population is expected to create a demand for effective treatments among patients. In addition, availability of a wide range of antiviral drugs to treat HSV infections including acyclovir, valacyclovir, and famciclovir. These drugs are available in both topical and oral formulations, and are used to treat both primary and recurrent HSV infections. Thus, rise in demand for these drugs drive the market growth.
Furthermore, government initiatives and policies to promote public health and increase access to healthcare also have a positive impact on the HSV treatment market. European countries have a well-established healthcare system, and they invest significantly in R&D of new treatments. This rise in healthcare expenditure is expected to boost the market for herpes simplex virus treatment.
The market also offers growth opportunities to the key players in the market. The increase in R&D activities for herpes simplex virus treatment is driving the growth of the market. For instance, UBP Greater China (Shanghai) Co., Ltd is conducting phase-ll clinical trial to evaluate the safety and efficacy of UB-621 in adults with recurrent genital herpes simplex virus-2 infection. Therefore, products under clinical evaluation are projected to provide lucrative opportunity for market growth. Many research organizations and pharmaceutical companies are investing in the development of novel treatment options for herpes simplex virus, which is expected to drive the market growth. Thus, rise in R&D activities for herpes simplex virus provides the lucrative opportunity to the market growth.
The herpes simplex virus treatment market is segmented into type, drug type, capacity, distribution channel and region. On the basis of type, the market is categorized into herpes simplex virus-1 infection, and herpes simplex virus-2 infection. On the basis of drug type, it is categorized into acyclovir, valacyclovir, famciclovir. On the basis of distribution channel, it is segmented into hospital pharmacies, drug store and retail pharmacies, Online providers Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The key players profiled in the study include Abbott Laboratories, Amneal Pharmaceuticals LLC., Emcure Pharmaceuticals Limited, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and Viatris Inc. The players in the market have been actively engaged in the adoption strategy such as product approval to remain competitive and gain advantage over the competitors in the market. For instance, in November 2020, Amneal Pharmaceuticals, LLC announced that it has received the approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%, generic version of Zovirax for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.
Key Market Insights
- By type, the herpes simplex virus-1 infection segment was the highest revenue contributor to the market and is estimated to reach $1,514.20 million by 2031, with a CAGR of 1.9%. However, the herpes simplex virus-2 infection segment is estimated to be the fastest-growing segment with a CAGR of 2.6% during the forecast period.
- By drug type, the valacyclovir segment dominated the global market in 2021.
- Based on distribution channel, the hospital pharmacies segment was the highest revenue contributor to the market with a CAGR of 1.5% during the forecast period. However, the online providers segment is estimated to be the fastest-growing segment during the forecast period.
- Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 2.8% during the forecast period.
Companies Mentioned
- Viatris Inc.
- Abbott Laboratories
- GlaxoSmithKline plc
- Pfizer Inc.
- Fresenius SE and Co. KGaA
- Amneal Pharmaceuticals LLC
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Emcure Pharmaceuticals Limited
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Related Reports
From
Herpes Simplex Virus Treatment Global Market Report 2024
- Report
- 200 Pages
- Global
From
From
From
Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2034
- Report
- 152 Pages
- Global
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
